1. Medtech Insight
  2. >>Business
  4. >>Clinical Trials

Abbott Seeks Expanded Labeling For CardioMEMS HF Monitor Based On GUIDE HF Results

 
• By Reed Miller

The GUIDE HF investigators contend the trial missed its primary endpoint because of COVID-19.

• Source: Abbott

The GUIDE HF trial missed its primary endpoint, but the trial's investigators contend the trial still showed that Abbott ’s CardioMEMS HF pulmonary artery pressure monitoring system can help reduce heart failure hospitalizations in patients with moderate heart failure.

JoAnn Lindenfeld of Vanderbilt University in Nashville presented the full one-year results from the 1,000-patient randomized arm of GUIDE HF at the European Society of Cardiology Congress on 27 August. The results were simultaneously published in 

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 
• By Natasha Barrow

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.

Mirvie Launches Predictive Blood Test For Preeclampsia

 
• By Marion Webb

Mirvie launched Encompass, a blood test to help identify women over age 35 who are at moderate risk for preeclampsia, and will conduct additional studies to support reimbursements from payers.

SpotitEarly Raised $20.3M In New Funding To Bring AI- And Dog-Sniffing-Powered Early Cancer Detection Test To US

 
• By Marion Webb

Israeli-based SpotitEarly hopes to bring an early cancer-detection test, which uses dogs’ noses to detect compounds in exhaled breath and AI analysis, to US homes in 2026.

LSX Europe: Women’s Health Education Is The Key For Unlocking VC Investment

 
• By Natasha Barrow

Flo Health was the first femtech unicorn to be valued at over $1bn. But the company faced 49 investment rejections before reaching that status, Anna Klepchukova, the company’s chief medical officer, told the LSX World Congress Europe. THENA Capital’s Esther Reynal de St Michel Richardot talked through the firm’s gender-smart investment strategy.

More from R&D